NMI-3377

NMI-3377 is a discontinued drug candidate that was developed by NitroMed, Inc. for the treatment of urogenital diseases, including urinary incontinence and overactive bladder. The compound was part of NitroMed's proprietary pipeline of nitric oxide-enhanced drugs, which utilized nitrosylation technology to incorporate nitric oxide-donating groups into therapeutic molecules. NMI-3377 was designed to act as a nitric oxide donor, leveraging the smooth muscle relaxant properties of nitric oxide to improve therapeutic outcomes in the urogenital tract. The drug's development was halted in the preclinical stage, and the specific parent molecule or primary molecular target beyond nitric oxide donation was not publicly disclosed before NitroMed's dissolution and asset divestiture.